ADAP Stock Price | Adaptimmune Therapeutics Plc P/E, Revenue, EPS, & Forecasts

Adaptimmune Therapeutics Plc • ADAP

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Adaptimmune Therapeutics Plc

Ticker

ADAP

Trading on

NASDAQ

ISIN

US00653A1079

Industry

Biotechnology

Sector

Healthcare

CEO

Adrian G. Rawcliffe

Headquarters

60 Jubilee Avenue, Abingdon, undefined, United Kingdom, OX14 4RX

Employees

449

Website

adaptimmune.com

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Metrics

BasicAdvanced

Market cap

$130M

P/E ratio

EPS

-$0.17

Dividend Yield

0.00%

Beta

2.51

Forward P/E ratio

EBIDTA

$-26.5M

Ex dividend date

Price & volume

Market cap

$130M

Average daily volume

1.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

0.11

Trailing P/E

Price to sales

0.74

Price to book

1.62

Earnings

EPS

-$0.17

EPS estimate (current quarter)

-$0.13

EPS estimate (next quarter)

-$0.11

EBITDA

$-26.5M

Revenues (TTM)

$175M

Revenues per share (TTM)

$0.71

Technicals

Beta

2.51

52-week High

$2.05

52-week Low

$0.46

50-day moving average

$0.59

200-day moving average

$0.87

Short ratio

9.73

Short %

4.21%

Management effectiveness

ROE (TTM)

52.96%

ROA (TTM)

7.69%

Profit margin

25.43%

Gross profit margin

$31.9M

Operating margin

35.89%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

458.80%

Share stats

Outstanding Shares

256M

Float

1.04B

Insiders %

0.32%

Institutions %

49.80%

Analyst Insights & forecasts

67% Buy

22% Hold

11% Sell

Based on information from 9 analysts.

Average price target

$2.30

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.24

-$0.10

140.00%

Q4 • 23Beat

-$0.18

-$0.10

80.00%

Q1 • 24Beat

$0.24

-$0.07

442.86%

Q2 • 24Beat

-$0.01

-$0.18

94.54%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$128M

$69.5M

54.22%

Q2 • 24

$40.9M

$-17.6M

43.07%

Q3 • 24

68.10%

125.34%

179.45%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$322M

$225M

70.07%

Q2 • 24

$317M

$237M

74.80%

Q3 • 24

1.33%

5.33%

6.75%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$47.4M

$-0.7M

$24.5M

$46.6M

Q2 • 24

$-54.5M

$-66M

$25M

$-54.9M

Q3 • 24

214.91%

8,785.33%

1.99%

217.70%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Adaptimmune Therapeutics Plc share?

Adaptimmune Therapeutics Plc shares are currently traded for undefined per share.

How many shares does Adaptimmune Therapeutics Plc have?

Adaptimmune Therapeutics Plc currently has 256M shares.

Does Adaptimmune Therapeutics Plc pay dividends?

No, Adaptimmune Therapeutics Plc doesn't pay dividends.

What is Adaptimmune Therapeutics Plc 52 week high?

Adaptimmune Therapeutics Plc 52 week high is $2.05.

What is Adaptimmune Therapeutics Plc 52 week low?

Adaptimmune Therapeutics Plc 52 week low is $0.46.

What is the 200-day moving average of Adaptimmune Therapeutics Plc?

Adaptimmune Therapeutics Plc 200-day moving average is $0.87.

Who is Adaptimmune Therapeutics Plc CEO?

The CEO of Adaptimmune Therapeutics Plc is Adrian G. Rawcliffe.

How many employees Adaptimmune Therapeutics Plc has?

Adaptimmune Therapeutics Plc has 449 employees.

What is the market cap of Adaptimmune Therapeutics Plc?

The market cap of Adaptimmune Therapeutics Plc is $130M.

What is the P/E of Adaptimmune Therapeutics Plc?

The current P/E of Adaptimmune Therapeutics Plc is null.

What is the EPS of Adaptimmune Therapeutics Plc?

The EPS of Adaptimmune Therapeutics Plc is -$0.17.

What is the PEG Ratio of Adaptimmune Therapeutics Plc?

The PEG Ratio of Adaptimmune Therapeutics Plc is 0.11.

What do analysts say about Adaptimmune Therapeutics Plc?

According to the analysts Adaptimmune Therapeutics Plc is considered a buy.